Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diasorin SpACHIX:DIAM 78 3-Year Book Growth Rate is 1.70% as of Jun. 2026, which is 90% below its 10-year median of 17.10. GuruFocus rates CHIX:DIAM with a GF Score™ of 78/100 and a GF Value™ of €88.84 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 57.81% on this metric.
During the past 12 months, Diasorin SpA's average Book Value per Share Growth Rate was 1.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 1.70% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 10.80% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 13.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Diasorin SpA was 156.90% per year. The lowest was 1.70% per year. And the median was 17.10% per year.
Diasorin SpA (CHIX:DIAm) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Diasorin SpA 3-Year Book Growth Rate Related Terms
CHIX:DIAM vs TMO, DHR, IDXX: 3-Year Book Growth Rate Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA 3-Year Book Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 1.70% mean?
Diasorin SpA (CHIX:DIAM) has a 3-Year Book Growth Rate of 1.70% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Diasorin SpA and its competitors. This is 90% below median its historical median of 17.10. Over the past decade, Diasorin SpA's 3-Year Book Growth Rate has ranged from 1.70 to 156.90. According to the industry distribution chart, Diasorin SpA ranks #81 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 42.2%.
Is Diasorin SpA's 3-Year Book Growth Rate too high?
Diasorin SpA's current 3-Year Book Growth Rate of 1.70% is 90% below median its 10-year median of 17.10. Over the past 10 years, this metric has ranged from a low of 1.70 to a high of 156.90. Based on the distribution chart, Diasorin SpA ranks #81 out of 192 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's 3-Year Book Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #81 out of 192 companies for 3-Year Book Growth Rate. This puts Diasorin SpA in the upper half of its industry. Historically, Diasorin SpA's own 3-Year Book Growth Rate has ranged from 1.70 to 156.90 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Diagnostics & Research company?
A good 3-Year Book Growth Rate depends on the Medical Diagnostics & Research industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Diasorin SpA and its competitors. Diasorin SpA's current 3-Year Book Growth Rate is 1.70%, which is 90% below median its own 10-year median of 17.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €88.84, compared to a current price of €74.53 — trading 16.1% below its estimated fair value. The current 3-Year Book Growth Rate is 1.70%, which is 90% below median its 10-year median of 17.10. Diasorin SpA's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current 3-Year Book Growth Rate is 1.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €74.53 is trading 16.1% below its estimated GF Value™ of €88.84.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for CHIX:DIAM:
3-Year Book Growth Rate: 1.70% (90% below median its 10-year median of 17.10)
GF Value™: €88.84 vs. price of €74.53 (16.1% below fair value)
No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score
Get the complete analysis for CHIX:DIAM
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIAM has been successfully added to your 
